ERG single gene test
Methodology
Molecular
Test Description and clinical significance
Genes
ERG
Disease:
Acute myeloid leukemia (AML), Ewing sarcoma, soft tissue sarcoma, prostate adenocarcinoma, lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, and breast invasive ductal carcinoma
Molecular test that utilizes NGS technology to detect mutations in ERG. This gene encodes a member of the erythroblast transformation-specific (ETS) family of transcriptions factors. All members of this family are key regulators of embryonic development, cell proliferation, differentiation, angiogenesis, inflammation, and apoptosis. The protein encoded by this gene is mainly expressed in the nucleus. It contains an ETS DNA-binding domain and a PNT (pointed) domain which is implicated in the self-association of chimeric oncoproteins. This protein is required for platelet adhesion to the subendothelium, inducing vascular cell remodeling. It also regulates hematopoesis, and the differentiation and maturation of megakaryocytic cells.
Specimen Requirements
Collection:
FFPE sections, 5-10 sections are recommended at 4 to 10 micron. A minimum of 20 ?l of RNA with a concentration of at least 5ng/?l and an OD260/280 ratio of 2.0-2.1 respectively, obtained on a spectrophotometer is required.
Stability:
FFPE blocks- Indefinitely/ FFPE Slides-4 weeks
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative. Insufficient specimen (less than 10% of tumor). Unlabeled or improperly labeled specimens. Decalcified specimens. Improperly stored RNA.
Storage & Transport
Store FFPE blocks and slides at room temperature. Genomic RNA must be stored at –60 to –85°C.
CPT(s)
81479
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
